Sareum Holdings PLC
SAR
Company Profile
Business description
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.
Contact
Langford Arch, London Road
Unit 2a, Pampisford
CambridgeCambridgeshireCB22 3FX
GBRT: +44 1223497700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
5
Stocks News & Analysis
stocks
What next for Tesla as 2024 deliveries disappoint?
Tesla shares started the year on a sour note. We think they continue to price in ambitious growth going forward.
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,511.90 | 46.90 | 0.55% |
| CAC 40 | 7,282.22 | 111.54 | -1.51% |
| DAX 40 | 19,906.08 | 118.58 | -0.59% |
| Dow JONES (US) | 42,732.13 | 339.86 | 0.80% |
| FTSE 100 | 8,223.98 | 36.11 | -0.44% |
| HKSE | 19,760.27 | 136.95 | 0.70% |
| NASDAQ | 19,621.68 | 340.88 | 1.77% |
| Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
| NZX 50 Index | 13,067.83 | 42.91 | -0.33% |
| S&P 500 | 5,942.47 | 73.92 | 1.26% |
| S&P/ASX 200 | 8,250.50 | 49.30 | 0.60% |
| SSE Composite Index | 3,211.43 | 51.13 | -1.57% |